This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), AstraZeneca (AZN) and Enbridge (ENB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
LMT HD FOX DB SAPGF AZN ENB MPC SE ENB SAP AZN CSCO MS OXY FOXA
Merck and Co., Inc. (MRK - Free Report) along with its Japanese partner Eisai Co., Ltd. announced that their tyrosine kinase inhibitor, Lenvima (lenvatinib) has received FDA approval for an expanded indication. Lenvima, has been approved by the FDA for first-line treatment of unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer which is difficult to treat.
MRK AZN AZN RDN NVS FAF
2018-08-14 zacks - 1
On Aug 13, we issued an updated research report on Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) . This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of treatments primarily addressing gastrointestinal (“GI”) diseases. The company’s sole marketed drug, Linzess, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (“CIC”).
4503 IRWD SGYP ALPMY AZN AGN ALPMF AZN SGYPW
Chicago, IL –August 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk (NVO - Free Report) , J&J (JNJ - Free Report) , Allergan (AGN - Free Report) , Editas Medicine, Inc. (EDIT - Free Report) , AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
MRK HD AZN EPM EDIT AGN AZN EPM-A BGSF
The year 2018 has emerged as quite a lucky one for Eli Lilly (LLY), as the company has gone ahead to raise its FY 2018 guidance not once but two times in a row. The company now expects revenues in the range of $24.0 - $25.0 billion for FY 2018, while non-GAAP EPS is expected in the range $5.40 - $5.50 (linked above).
ARMO AZN AZN PFE
Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) reported second-quarter 2018 adjusted loss of 28 cents per share, wider than the Zacks Consensus Estimate of a loss of 19 cents and in line with the year-ago period.
4503 IRWD VRTX ALPMY AZN AGN ALPMF AUROPHARMA AZN 524804 ARBQY
Pfizer’s (PFE - Free Report) strong second-quarter results stole the show this week. Other than that, the European Commission approved Pfizer’s first oncology biosimilar and a second indication for its JAK inhibitor, Xeljanz and Bristol-Myers’ (BMY - Free Report) Opdivo for a melanoma indication. Meanwhile, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave its opinion recommending/not recommending approval of several drugs in Europe.
MRK AZN AZN NVS PFE SNY
TESARO, Inc. (TSRO - Free Report) incurred a loss of $3.04 per share in the second quarter of 2018, which was wider than the Zacks Consensus Estimate of a loss of $2.66 as well as the year-ago loss of $2.82 per share. However, the adjusted loss (excluding share-based compensation) for the reported quarter was $2.52 per share.
TSRO AZN CY AZN JNJ CLVS
Big pharma drug makers and biotech issues continue to top the healthcare sector by yield and broker targets. WallStars are distinguished by positive broker target price upsides.
ABT GILD AZN MCK CVS ABT GSK SNY PDCO AZN AGN PMD NVS GSK ABBV CAH PFE ABBV
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...